Abstract
We investigated the long-term efficacy and tolerability of add-on Topiramate, used under placebo- controlled conditions, in 13 adult refractory epileptic patients, mostly with complex partial seizures. Overall, 4 patients (33%) were still on Topiramate (400 to 1000 mg/daily) after a mean period of 30 months. CNS-related side effects occurred in 10 patients and were usually transitory and mild. We conclude that Topiramate maintains its benefit on long-term follow-up in one third of the patients initially exposed to the study drug.
Translated title of the contribution | Topiramate in the treatment of drug-resistant epilepsy: A long-term follow-up study |
---|---|
Original language | Italian |
Pages (from-to) | 255-256 |
Number of pages | 2 |
Journal | Bollettino - Lega Italiana contro l'Epilessia |
Issue number | 95-96 |
Publication status | Published - 1996 |
ASJC Scopus subject areas
- Clinical Neurology